INS and type 2 diabetes mellitus: The introduction of newer oral and injectable therapies, some with favourable cardiovascular profiles or with other benefits such as low risk of hypoglycaemia or weight loss,2 may delay initiation of insulin treatment to later stages of T2DM than before.